Cadila Pharmaceuticals has launched Ciledge Trio, a fixed-dose combination therapy aimed at delivering sustained blood ...
CalciMedica’s stock nosedived after the biotech abandoned a phase 2 study of its calcium release-activated calcium (CRAC) channel inhibitor in patients with acute kidney injury (AKI) over a “safety ...
If you have hypertrophic cardiomyopathy (HCM) and are experiencing symptoms such as shortness of breath, chest pain, dizziness, and difficulty exercising, your doctor might suggest that you start ...
SAN DIEGO, Jan. 6, 2026 /PRNewswire/ -- HUYABIO International today announced favorable Phase 1 clinical data for HBI-3000, a novel bioinspired investigational drug with promising antiarrhythmic ...
High blood pressure affects 1 in 3 U.S. adults and can lead to serious health problems like heart disease and stroke. While medication helps, nutrition, exercise, and even certain herbs and spices can ...
In this important manuscript, Cassell and colleagues set out on a mechanistic and pharmacological exploration of an engineered chimeric small conductance calcium-activated potassium channel 2 (SK2).
Tumor necrosis factor-α (TNF-α) is considered a potential therapeutic strategy for cancers, as it exacerbates calcium influx through voltage-gated calcium channels (VGCCs), thereby inducing apoptosis.
The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results